Despite Benefits, IP/IV Chemo Combo Underused in Ovarian Cancer

Article

Despite trials showing a benefit when combining IP and IV chemo for ovarian cancer, fewer than 50% of eligible patients are currently receiving this treatment.

Despite clinical trials showing a benefit for combined use of intraperitoneal (IP) and intravenous (IV) chemotherapy for the treatment of ovarian cancer, fewer than 50% of eligible patients are currently receiving this treatment in clinical practice, according to the results of a study published in the Journal of Clinical Oncology.

In 2006, the results of the Gynecologic Oncology Group (GOG)-172 trial demonstrated a 16-month improvement in the median overall survival of women with ovarian cancer treated with combined IP/IV therapy compared with IV therapy alone.

In the current trial, Alexi A. Wright, MD, of Dana-Farber Cancer Institute, and colleagues wanted to examine if the use of this combined regimen was feasible and effective in clinical practice.

The researchers conducted a prospective study looking at 823 women diagnosed with stage III optimally cytoreduced ovarian cancer between 2003 and 2012 at six National Comprehensive Cancer Network (NCCN) institutions. IP/IV chemotherapy use was examined in the first cohort, and survival and treatment-related toxicities were examined in a propensity score–matched sample of 402 patients diagnosed between 2006 and 2012.

From 2003 to 2006, the use of IP/IV chemotherapy increased from 0% to 33%, with a further increase to 50% from 2007 to 2008. Despite these increases, the use of IP/IV therapy varied greatly from institution to institution between 2006 and 2012 from a rate of 4% to 67% (P < .001). Overall, 43% of patients who received IP/IV therapy received a modified regimen.

The researchers’ analysis found that younger women and those with fewer comorbidities were more likely to received IP/IV chemotherapy compared with IV chemotherapy (P < .002 for both).

In the group of 402 women, the researchers found that IP/IV chemotherapy was associated with a 3-year overall survival of 81% compared with 71% among women treated with IV chemotherapy alone for a hazard ratio [HR] of 0.68 (95% confidence interval [CI], 0.47–0.99).

“In a sensitivity analysis, the adjusted HRs ranged from 0.61 to 0.76 on excluding each institution one by one, indicating that the survival benefit observed was not driven by outcomes at a single institution,” the researchers wrote.

Women assigned IP/IV chemotherapy had higher rates of anemia and hospitalization compared with IV chemotherapy alone. In addition, women assigned IP/IV therapy had a higher odds of presenting with distant disease at first recurrence (58.8% vs 29.4%) than those women treated with IV chemotherapy alone.

“Despite frequent modifications to the GOG-172 regimen, we found that use of IP/IV chemotherapy in clinical practice is feasible and associated with improved survival compared with IV chemotherapy, consistent with results from randomized trials,” Wright and colleagues wrote, suggesting that “IP/IV is an important and possibly underused, evidence-based treatment strategy for improving outcomes in ovarian cancer.”

Related Videos
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content